Daxton Duncan, NP
Family · Terre Haute, INNPI 1851757983
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Saluda Medical Americas, Inc. accounts for 60.2% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $16,246, 9.0 times the $1,812 reported in 2021. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $112.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Saluda Medical Americas, Inc.$18K
- Abbott$6K
- Boston Scientific$2K
- Relievant Medsystems, Inc.$2K
- Medtronic$600
- MML US, Inc.$442
- plus $2K from 20 others
What the payments were for
- Consulting fees$11,39837%
- Speaking & faculty fees$1,8796%
- Travel & lodging$9,95432%
- Food & beverage$7,43224%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Saluda Medical Americas, Inc. | 77 | $18,448 |
| Abbott | 47 | $6,166 |
| Boston Scientific | 28 | $1,726 |
| Relievant Medsystems, Inc. | 5 | $1,584 |
| Medtronic | 9 | $600 |
| MML US, Inc. | 10 | $442 |
| Vertos Medical, Inc. | 3 | $337 |
| Amgen | 37 | $329 |
| Radius Health, Inc. | 11 | $178 |
| Arbor Pharmaceuticals, Inc. | 5 | $102 |
| Azurity Pharmaceuticals, Inc. | 5 | $89 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $78 |
| Vertex | 3 | $74 |
| Novo Nordisk | 4 | $72 |
| Indivior Inc. | 4 | $67 |
| Collegium Pharmaceutical, Inc. | 3 | $56 |
| AbbVie | 3 | $53 |
| Averitas Pharma Inc. | 2 | $45 |
| AstraZeneca | 2 | $40 |
| IBSA Pharma Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $34 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| Gilead | 1 | $23 |
| Si-bone, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evoke$17,281
- Intracept$3,235
- PROCLAIM$3,119
- Proclaim IPG$1,450
- Superion Indirect Decompression System$1,008
- Axium$938
- mild Device Kit$330
- ReActiv8$257
- INTELLIS ADAPTIVESTIM$196
- SYNCHROMEDII$101
How this compares
$30,662 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HorizantGabapentin Enacarbil | 18 | $20,284 |
| BelbucaBuprenorphine Hcl | 23 | $15,981 |
| Pregabalin | 258 | $12,241 |
| Gabapentin | 449 | $7,511 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 299 | $6,341 |
| Buprenorphine | 13 | $5,872 |
| Celecoxib | 77 | $3,272 |
| Lidocaine | 15 | $1,822 |
| Cyclobenzaprine Hcl | 127 | $1,375 |
| Oxcarbazepine | 27 | $1,153 |
| Methocarbamol | 44 | $903 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 37 | $885 |
| Amitriptyline Hcl | 35 | $755 |
| Tizanidine Hcl | 55 | $733 |
| Baclofen | 36 | $679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Arbor Pharmaceuticals, Inc.Horizant | $102 | $20,28418 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $56 | $15,98123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Terre Haute
- Stephanie ArnoldTerre Haute$52K
- Melinda FuquaTerre Haute$19K
- Tamara GormanTerre Haute$16K
- Kathy BannonTerre Haute$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.